Evidence map›Paper›PMID 36620051›Full record

ReviewFrontiers in microbiology2022

Novel perspectives on antisense transcription in HIV-1, HTLV-1, and HTLV-2.

Edward Lin, Amanda R Panfil, Grace Sandel, Pooja Jain

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. YTHDF1 and YTHDC1 mJournal of virology · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edward LinDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Amanda R PanfilDepartment of Veterinary Biosciences, Center for Retrovirus Research, The Ohio State University, Columbus, OH, United States.
Grace SandelDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.
Pooja JainDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, United States.

Funding

Role of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Lee Ratner · 2003 to 2026
$44.8M
Pre-clinical testing of a novel immunotherapy for HTLV-induced neurologic diseaseR01NS097147 · NINDS · DREXEL UNIVERSITY · PI JAIN, POOJA · 2017 to 2021
$2.2M
NCI NIH HHS P01 CA100730NINDS NIH HHS R01 NS097147
6 · The paper itself

Abstract

The genome of retroviruses contains two promoter elements (called long terminal repeat or LTR) at the 5' and 3' end of their genome. Although the expression of retroviral genes generally depends on the promoter located in the 5' LTR, the 3' LTR also has promoter activity responsible for producing antisense transcripts. These natural antisense transcripts (NATs) are a class of RNA molecules transcribed from the opposite strand of a protein-coding gene. NATs have been identified in many prokaryotic and eukaryotic systems, as well as in human retroviruses such as human immunodeficiency virus type 1 (HIV-1) and HTLV-1/2 (human T-cell leukemia virus type 1/2). The antisense transcripts of HIV-1, HTLV-1, and HTLV-2 have been briefly characterized over the past several years. However, a complete appreciation of the role these transcripts play in the virus lifecycle and the cellular factors which regulate their transcription is still lacking. This review provides an overview of antisense transcription in human retroviruses with a specific focus on the MEF-2 family of transcription factors, the function(s) of the antisense protein products, and the application of antisense transcription models in therapeutics against HIV-1 and HTLV-1 in the context of co-infection.

Indexed as

antisense transcriptionHIV-1HTLV-1HTLV-2MEF-2

Identifiers

PMID36620051
PMCPMC9822710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.